Romisan (Omeprazole)

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Romisan (Omeprazole)

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule, Oral suspension, IV powder
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Gastric acid suppression
Origin Synthetic substituted benzimidazole

Romisan (Omeprazole): Definition and Pharmacological Classification

Romisan is a recognized brand name for the drug Omeprazole, a highly potent medication that belongs to the Proton Pump Inhibitor (PPI) class. Omeprazole is a synthetic compound derived from the substituted benzimidazole chemical structure, defining it as a specialized type of gastric acid secretion inhibitor. As such, it is a medication used to decrease the amount of acid made in the stomach.

This classification is based on its fundamental action, which is clinically recognized for achieving superior and more sustained acid suppression compared to older classes of antacids. As a single-ingredient product, its identity is rooted entirely in its specific chemical composition and its highly targeted anti-secretory effect. In many markets, Omeprazole formulations, including certain doses of Romisan, are categorized as prescription-only medications, confirming their role in managed care.

Composition, Form, and General Purpose

Omeprazole is designed for systemic action, most commonly administered via the oral route as a delayed-release capsule or oral suspension, although a powder for intravenous injection (IV) form is also utilized. The active substance, Omeprazole, is chemically acid-labile, meaning it is rapidly degraded by the stomach's own acid before it can be absorbed. Consequently, specialized gastro-resistant preparations are necessary for Omeprazole to ensure its therapeutic effect.

To overcome this structural limitation, the delayed-release capsule contains hundreds of microscopic enteric-coated granules. This protective formulation is critical, as the coating ensures that the drug bypasses the stomach intact and dissolves safely in the small intestine, where it can be absorbed into the bloodstream. The general purpose of this carefully engineered delivery is to reliably achieve consistent, significant, and sustained gastric acid suppression, a mechanism essential for addressing conditions where the stomach's corrosive environment is problematic.

Regulatory References

  1. MedlinePlus confirms Omeprazole’s classification
Advertisements

What side effects are possible with Romisan (Omeprazole)?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Omeprazole by the frequency and type of documented adverse reactions. These classifications establish the expected risk profile, separating common, less severe effects from rare, clinically significant events.


Frequency-Classified Adverse Reactions

The most frequently reported adverse effects are categorized as Common (affecting up to 1 in 10 patients) and primarily involve the nervous and gastrointestinal systems. These include headache, abdominal pain, diarrhea, constipation, flatulence, nausea, and vomiting.

Uncommon reactions (affecting up to 1 in 100 patients) may involve insomnia, dizziness, somnolence, and temporary increase in liver enzyme values.

Serious and Systemic Reactions

Adverse reactions classified as Rare or Very Rare are clinically significant. Rare reactions (affecting up to 1 in 1,000 patients) include serious hypersensitivity reactions such as anaphylactic shock and angioedema, as well as blood disorders like leukopenia or thrombocytopenia. Very Rare reactions (affecting fewer than 1 in 10,000 patients) include severe skin conditions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and hepatic failure.

Duration-Related Safety Patterns

The official safety profile highlights specific risks associated with long-term use (typically over one year). These documented patterns include an increased risk of bone fractures of the hip, wrist, or spine, and the development of hypomagnesaemia (low serum magnesium levels). Prolonged exposure may also be linked to vitamin B12 deficiency and an increase in gastrointestinal infections.

Advertisements

Overdose and Emergency Response

Romisan (Omeprazole) Overdose and When to Seek Help

Overdosage with omeprazole has been documented to present with a cluster of generally transient clinical manifestations. According to regulatory documents, the observed signs include confusion, drowsiness, blurred vision, headache, and nausea. Other reported physical changes may involve the cardiovascular system, such as tachycardia (fast heartbeat), flushing, and diaphoresis (increased sweating), as well as dryness of the mouth.

Regulators classify these symptoms as temporary, and no serious clinical outcomes have been formally reported in connection with omeprazole overdosage.

Emergency Management and Action

If an overdose is suspected, official guidance instructs individuals to immediately contact the poison control helpline. As no specific antidote is known for omeprazole, management in clinical settings is focused on providing symptomatic and supportive treatment. Due to its high plasma protein binding, the substance is not readily dialyzable.

When to Seek Immediate Medical Attention

Urgent medical services must be contacted immediately if a person who has taken an overdose shows signs of severe clinical distress. This includes instances of collapse, having a seizure, experiencing trouble breathing, or inability to be awakened, as stipulated by public health authorities.

Advertisements

Therapeutic Uses of Romisan (Omeprazole)

Omeprazole is relevant for easing certain distressing symptoms associated with increased discomfort or tension. It provides support that helps ease the overall symptom burden, assisting patients with maintaining functional stability.

Omeprazole is commonly used to help with conditions characterized by periods of heightened symptoms, such as Gastroesophageal Reflux Disease (GERD), various forms of ulcers (gastric and duodenal), and hypersecretory conditions.


Easing Symptoms of Acute Heartburn and Indigestion

Omeprazole is often used when symptoms intensify and supportive relief is needed for sudden episodes of heartburn and acid indigestion. It is relevant for managing symptoms that interfere with daily comfort, contributing to improved comfort during periods of heightened symptoms. This is generally applied in contexts where additional symptomatic support is needed for symptoms related to heightened physiological activity.


Supportive Management for Persistent Acid Reflux Disease (GERD)

This medication is applicable in conditions marked by increased physiological stress, such as GERD. It is relevant in clinical settings marked by heightened patient distress, used across domains where short-term symptom management is appropriate to manage symptoms that create noticeable interference with daily stability.


Relief for Challenging Gastric Manifestations

Omeprazole is relevant in situations involving recurrent or episodic manifestations, such as those associated with erosive esophagitis. It is applied during phases where the patient experiences heightened discomfort, offering symptomatic relief that helps patients cope more steadily and supports the patient during difficult episodes by easing distress. It is commonly used when short-term symptomatic assistance is needed for symptoms linked to organ-specific functional stress.


Quick Fact: Relief for Persistent Burning Pain

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Romisan (Omeprazole)?

Official regulatory documents strictly define the patient groups eligible for Omeprazole use.


Contraindicated Populations (Must Not Use)

Category Regulatory Status
Hypersensitivity Absolutely contraindicated in patients with known allergy to omeprazole, substituted benzimidazoles, or any component of the formulation.
Concomitant Drugs Contraindicated for patients receiving specific antiviral medications, including nelfinavir and rilpivirine-containing products.

Age-Based Eligibility

Age Group Eligibility Status
Infants (<1 year) Safety and effectiveness have not been established by regulatory authorities.
Children (ge 1 year) & Adults Use is approved for specific therapeutic conditions.
Geriatric Patients Use is permitted; no dose adjustment is necessary based on age alone.

Conditions Requiring Restricted Use

Use is conditional in patients with Hepatic Impairment (liver disease), where official labeling states that dose reduction should be considered. Use is also restricted in patients taking Clopidogrel, with regulatory warnings advising against concomitant use. Eligibility requires clinical exclusion of gastric malignancy, as the medicine's effect does not rule out the presence of cancer.

Advertisements

What should I know about interactions with other medicines?

Romisan (Omeprazole) can significantly alter the concentrations of co-administered medicines, requiring management or avoidance of certain combinations as mandated by official labeling. The drug acts primarily through two main mechanisms documented in regulatory information: gastric pH elevation and inhibition of the CYP2C19 enzyme.

The change in stomach acidity reduces the absorption and effectiveness of several drugs that rely on an acidic environment for solubility, including Ketoconazole, Itraconazole, and the antiretrovirals Atazanavir and Nelfinavir. Regulatory documents advise against or do not recommend co-administration with these specific antiretrovirals due to the risk of treatment failure.

As a CYP2C19 inhibitor, Omeprazole can increase the systemic exposure of drugs metabolized by this enzyme, such as Diazepam and Cilostazol. This inhibition also interferes with the activation of the antiplatelet medicine Clopidogrel, potentially diminishing its effectiveness; therefore, co-administration is officially constrained. Furthermore, Omeprazole may increase the plasma levels of Tacrolimus and Methotrexate. For high-dose Methotrexate, regulatory bodies suggest considering temporary withdrawal of Omeprazole to prevent prolonged serum concentrations. Strong inducers of drug metabolism, like Rifampin and St. John’s Wort, can significantly decrease Omeprazole levels, and their co-administration is discouraged.

Advertisements

Mechanism of Action

How Romisan (Omeprazole) Works

Omeprazole functions as a selective, irreversible inhibitor of the gastric H^+/K^+ ATPase enzyme, commonly known as the Proton Pump. This enzyme is the final molecular mechanism responsible for acid secretion in the parietal cells of the stomach lining. The drug is administered as an inactive prodrug and must first concentrate and undergo acid-catalyzed conversion into its active sulfenamide intermediate within the highly acidic secretory canaliculi.

The activated intermediate then forms a covalent disulfide bond with specific cysteine residues on the Proton Pump's structure, physically and permanently disabling the enzyme. This direct molecular blockade halts the final transport of hydrogen ions ( H^+) into the stomach lumen, resulting in a significant and prolonged reduction in gastric acid output.

Since the inhibition is irreversible and targets only actively secreting pumps, maximal suppression requires multiple doses to disable a sufficient number of enzyme units as they cycle into activation. The restoration of acid-secreting function is determined solely by the physiological rate of the body synthesizing new H^+/ K^+ ATPase enzyme.

Advertisements

Dosage and Administration Information

Official Dosing and Administration Guidelines

Omeprazole (Romisan) is administered via the oral route as delayed-release capsules, tablets, or oral suspension, and by intravenous (IV) infusion when oral therapy is not feasible.

Standard Adult Regimens and Frequency

Regimen Feature Official Regulatory Guidance
Dose Range Typically 20 mg or 40 mg once daily. Doses for pathological hypersecretory conditions (PHC) start at 60 mg once daily and may be adjusted up to 360 mg per day.
Frequency Once daily (QD) is standard. Doses exceeding 80 mg daily (for PHC) must be administered in divided doses (e.g., Twice Daily, BID).
Duration Short-term treatment is generally 4 to 8 weeks. Maintenance of healing may be prescribed for up to 12 months.

Administration Instructions and Dose Adjustments

Oral Intake Conditions:

The delayed-release capsules or tablets must be swallowed whole and must not be crushed or chewed to preserve the protective enteric coating. The medication should be taken before eating, preferably in the morning. For patients with swallowing difficulty, the capsule pellets may be opened and mixed with a spoonful of applesauce or water and swallowed immediately, without chewing.

Special Population Dosing:

  • Hepatic Impairment: A dose reduction to 10 mg to 20 mg daily may be sufficient in patients with hepatic impairment.
  • Renal Impairment/Older Adults: Dose adjustment is not needed.
  • Pediatric Dosing: Dosing for children is determined based on body weight.
Advertisements

Recent Clinical Evidence

Romisan (Omeprazole): Recent Clinical Evidence

Clinical evidence for omeprazole, a proton pump inhibitor (PPI), primarily focuses on its role in reducing gastric acid secretion to address acid-related gastrointestinal disorders. Research has extensively investigated its use across several key conditions.


Efficacy and Indications

Studies support the use of omeprazole for conditions including Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE), and the treatment of gastric and duodenal ulcers. Randomized controlled trials (RCTs) typically report on healing rates and symptom resolution over short-term (4 to 8 weeks) treatment periods. For instance, data indicates that omeprazole is associated with higher rates of EE healing and better symptom control compared to placebo and certain older acid-suppressing agents.

Recent research has also examined omeprazole in combination with antibiotics for the eradication of Helicobacter pylori infection, which is a major factor in ulcer recurrence. Combination therapy is generally associated with a reduced risk of ulcer relapse.


Safety Profile and Long-Term Use

Clinical trials consistently report that omeprazole is generally well-tolerated in the short term. The most common adverse events noted in controlled studies include headache, abdominal pain, diarrhea, and nausea.

For long-term and chronic use, research has explored potential associations with various outcomes. These include potential links to an increased risk of bone fracture (hip, wrist, or spine) and deficiencies in certain micronutrients, such as Vitamin B-12. Healthcare providers may monitor individuals on prolonged therapy for these effects. Additionally, prolonged use has been associated with the formation of fundic gland polyps. All individuals should consult with a healthcare professional to determine the appropriate duration and suitability of this treatment.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Romisan (Omeprazole) (FAQ)

Q: What is the difference between Romisan and other stomach medicines like antacids?

A: According to regulatory classification, Romisan (Omeprazole) is a Proton Pump Inhibitor (PPI) that works by specifically and permanently blocking the final acid-producing pump in the stomach lining. This action is distinct from common antacids, which operate by chemically neutralizing acid that has already been secreted in the stomach.

Q: Is it possible to take Romisan long term?

A: Official guidance suggests using the lowest effective dose for the shortest period necessary. While some regulatory documents approve use for maintenance of healing for periods up to 12 months, warnings note that chronic use is associated with potential risks, including an increased risk of bone fracture and low magnesium levels.

Q: Does Romisan change the way my liver works?

A: Official safety documents list a temporary increase in liver enzyme values as an uncommon adverse reaction. For individuals with existing liver conditions (hepatic impairment), official safety information states that special consideration regarding dose adjustment may be necessary due to altered metabolism.

Q: Does Romisan affect calcium levels or bone density?

A: Regulatory documents include warnings about an increased risk of bone fracture, particularly in the hip, wrist, or spine, associated with long-term or high-dose use of omeprazole. This information is noted in the medication's safety profile related to mineral health.

Q: Are there any vitamins or supplements that should not be taken with Romisan?

A: Official safety information notes a specific interaction with the herbal supplement St. John’s Wort, and regulatory documents discourage co-administration as it may decrease the levels of omeprazole in the body.

Q: Does Romisan change the acidity in the whole body?

A: The drug’s mechanism is highly targeted to suppress the secretion of acid only in the parietal cells of the stomach lining. Official product information confirms the effect is localized to gastric acid output and does not significantly alter the overall acid balance of the rest of the body.

Q: Is Romisan available over-the-counter or only by prescription?

A: Omeprazole is available as both a prescription drug and, in a lower dose (typically 20 mg), as an over-the-counter (OTC) treatment for frequent heartburn in many markets. The prescription and non-prescription forms are subject to different regulatory conditions.

Q: Does Romisan interact with antidepressants or anxiety medicines?

A: Regulatory documents confirm omeprazole can interact with some medicines in these classes, such as the antidepressant citalopram and the anxiety medicine diazepam. This is because omeprazole can interfere with the metabolism of these drugs via the CYP2C19 enzyme system.

Q: What is the difference between delayed-release and immediate-release Omeprazole?

A: Delayed-release omeprazole is specifically coated (enteric-coated) to pass through the stomach acid intact. Immediate-release omeprazole uses an antacid, such as sodium bicarbonate, for acid protection, which may result in a more rapid absorption compared to the delayed-release formulation.

Q: Is it normal to feel tired when taking Romisan?

A: Official product information lists somnolence (drowsiness or sleepiness) as an uncommon side effect. Insomnia (difficulty sleeping) is also noted as an uncommon reaction in the regulatory documents.

Q: Do older adults react differently to Romisan than younger adults?

A: Regulatory documents generally state that no dose adjustment is required for older adults based on age alone. However, official information notes that the metabolism rate of omeprazole is somewhat reduced and its availability in the body may be increased in older subjects.

Q: How quickly should I expect Romisan to start working?

A: According to official pharmacodynamics data, the initial onset of the acid-suppressing effect typically occurs within one hour after the medication is taken. The maximum acid suppression is generally seen within two hours.

Q: Are there any major food or drink restrictions while taking Omeprazole?

A: While the medication is generally taken before a meal, official labels mention that minimizing intake of known heartburn-causing foods is a general practice for managing acid symptoms. Such foods often include rich, spicy, fatty foods, chocolate, caffeine, and alcohol.

Q: Can Romisan be taken with pain relievers like ibuprofen or aspirin?

A: Regulatory documents do not list a direct interaction with common pain relievers like ibuprofen. However, they do include warnings about the risk of gastrointestinal complications, as using nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin can increase the risk of GI bleeding or ulceration, especially in patients with existing risk factors.

Q: Is Romisan safe to use during pregnancy?

A: Omeprazole is currently classified by the FDA as Pregnancy Category C. This category indicates that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.

Q: What is the 'rebound' effect people mention when stopping Omeprazole?

A: The phenomenon people refer to is related to the drug’s pharmacological effect ceasing. Official documents state that when the drug is discontinued, acid-secretory activity gradually returns to pretreatment levels over approximately three to five days.

Q: Does Romisan interact with blood thinners like warfarin?

A: Omeprazole can interact with the blood thinner warfarin. Official documents indicate that co-administration may necessitate monitoring of the International Normalized Ratio (INR) and prothrombin time to detect possible changes.

Q: How does the way Romisan works compare to Zantac (Ranitidine) or Pepcid (Famotidine)?

A: Omeprazole is a Proton Pump Inhibitor (PPI) that permanently disables the acid-secreting pump. Official product information explicitly notes that omeprazole does not operate through H2-histamine antagonism, which is the mechanism used by medicines like Ranitidine and Famotidine.

Q: Why is Romisan usually taken before a meal?

A: The medication is usually taken before a meal because it works most effectively by blocking the acid pumps that are actively secreting. Taking it before eating ensures the drug is available in the body when the acid pumps are stimulated by the consumption of food.

Q: Does Romisan affect my ability to drive?

A: Official safety documents list side effects such as dizziness and somnolence (drowsiness). The presence of these central nervous system effects means that caution is a regulatory consideration when performing tasks that require mental alertness, such as driving or operating heavy machinery.

Q: How long does Romisan stay in my system after I stop taking it?

A: According to official pharmacokinetics data, the plasma half-life of omeprazole is short, typically ranging from 0.5 to 1 hour in healthy subjects. However, because the drug irreversibly blocks the acid pump, its clinical effect on acid suppression lasts much longer.

Q: Is Omeprazole safe for use while breastfeeding?

A: Regulatory labels note that limited data suggest omeprazole may be present in human milk. Official labeling highlights the necessity of weighing the mother's clinical need against any potential risk to the breastfed infant.

Q: Does Omeprazole interact with anti-seizure medications?

A: Official product information confirms that omeprazole can interact with some anti-seizure medications, such as phenytoin, which are metabolized by the CYP P450 enzyme system. Official documents indicate that monitoring of the anti-seizure medication's levels and potential dose adjustments are regulatory considerations.

Advertisements

How should Romisan (Omeprazole) be stored and disposed of?

How to Store and Dispose of Romisan (Omeprazole)?

Omeprazole delayed-release capsules and tablets must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F). The medication must be kept safe by storing it in its original container and ensuring it is protected from moisture. All forms must be kept out of the sight and reach of children.

Special Storage and Disposal Rules

Type Storage Condition Disposal Instruction
Delayed-Release Capsules/Tablets Store at Controlled Room Temperature; do not refrigerate. Do not dispose of via wastewater or household trash.
Reconstituted Suspension Must be refrigerated (2 C to 8 C) and discarded after 30 days. Dispose of unused product according to local regulations (e.g., take-back programs).

Contents of an opened capsule, if mixed, must be swallowed immediately and must not be saved for later use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Romisan (Omeprazole) found in:

A-Z Index: